Comparing Efficacy and Safety of Atogepant and Rimegepant for Migraine PreventionMarch 14, 2024Headache & Migraine
OnabotulinumtoxinA Reduces Interictal Burden and Allodynia Severity in Chronic MigraineMarch 14, 2024Headache & Migraine
Atogepant Effective and Safe in Pretreated Episodic Migraine, Shows Phase 3 StudyMarch 14, 2024Headache & Migraine
Meta-analysis Shows Link Between Shift Work and Risk for Headache and MigraineMarch 14, 2024Headache & Migraine
Comparative Efficacy of Lasmiditan and Calcitonin Gene-Related Peptide-Antagonists for MigraineFebruary 21, 2024Headache & Migraine
Habitual Intake of Caffeinated Beverages May Not Trigger Headache in Episodic MigraineFebruary 21, 2024Headache & Migraine
Comparing Real-World Efficacy of Anti-CGRP mAb vs OnabotulinumtoxinAFebruary 21, 2024Headache & Migraine
Resuming Anti-CGRP Monoclonal Antibodies Effective for Migraine PreventionFebruary 21, 2024Headache & Migraine
